CBU
INDV icon

CIBC Bancorp USA’s Indivior Pharmaceuticals INDV Stock Holding History

CIBC Bancorp USA’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$312K Buy
+12,932
New +$271K ﹤0.01% 1061

Other funds holding INDV

TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DSCM
Divisadero Street Capital Management Miami, Florida $2.39B AUM 134.55% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return

CIBC Bancorp USA's INDV Position: Q3 2025 in Review

CIBC Bancorp USA opened a new position in Indivior Pharmaceuticals (INDV) in Q3 2025: 12,932 shares worth $312K. The stake represents ﹤0.01% of the portfolio and ranks #1061 among its holdings.

198 funds tracked by Wall St. Rank hold INDV as of Q3 2025.

  • CIBC Bancorp USA held 12,932 shares of Indivior Pharmaceuticals worth $312K as of Q3 2025.
  • Indivior Pharmaceuticals was a new CIBC Bancorp USA position in Q3 2025.
  • Indivior Pharmaceuticals made up ﹤0.01% of CIBC Bancorp USA's portfolio in Q3 2025, its #1061 holding.
  • 198 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q3 2025.

Based on CIBC Bancorp USA's 13F filing for Q3 2025, filed 12 Nov 2025.